|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
ReCor Medical Reports 100% Responder Rate at One-Year Follow-up in Clinical Trial of Its Ultrasound-Based PARADISE™ Renal Denervation System for Treating Resistant Hypertension, a Major Risk Factor for Cardiovascular Disease
11/5/2012 9:51:04 AM
MENLO PARK, Calif.--(BUSINESS WIRE)--ReCor Medical reported one-year follow-up data on patients who have been treated via renal denervation for their resistant hypertension with the Company’s PARADISE® System—the only CE-marked system for renal denervation that is based on ultrasound, not radiofrequency, energy. The data were presented at TCT 2012 from the podium by Peter Fitzgerald, M.D., Ph.D., Associate Professor of Medicine (Cardiology), Associate Professor of Electrical Engineering (by courtesy), and Co-Director of the Center for Research in Cardiovascular Interventions at Stanford University School of Medicine. Additionally, Dr. Fitzgerald serves as Director of Core Cardiovascular Analysis Lab at Stanford.
|
|
|
|
|
|
|
|
|
|
|